Azacitidine Seacross 25 mg/mL powder for suspension for injection

DRUG2 trials

Sponsors

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, Ascentage Pharma Group Inc.

Conditions

Acute Myeloid Leukemia (AML)Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Phase 3

HOVON 177: Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy

RecruitingCTIS2024-512733-32-00

Hemato-Oncologie voor Volwassenen Nederland (Hovon) StichtingAcute Myeloid Leukemia (AML)

Start: 2025-03-31Target: 311Updated: 2026-01-27

A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4)

RecruitingCTIS2024-517247-31-00

Ascentage Pharma Group Inc.Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Start: 2025-07-07Target: 371Updated: 2026-01-16